Literature DB >> 30366921

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.

Romanos Sklavenitis-Pistofidis1, Marzia Capelletti1, Chia-Jen Liu1, Mairead Reidy1, Oksana Zavidij1, Daisy Huynh1, Patrick Henrick1, Alexandra Savell1, Kaitlen Reyes1, Bradley Rivotto1, Mark Bustoros1, Adriana Perilla-Glen1, Lorenzo Trippa2, Jorge J Castillo1, Steven P Treon1, Irene M Ghobrial1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30366921      PMCID： PMC6293872          DOI： 10.1182/blood-2018-07-863241

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  21 in total

1.  ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.

Authors:  Zheng Chen; Albert E Teo; Nami McCarty
Journal:  Clin Cancer Res       Date:  2015-09-08       Impact factor: 12.531

2.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

3.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

4.  Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.

Authors:  Jorge J Castillo; Kirsten Meid; Joshua N Gustine; Toni Dubeau; Patricia Severns; Zachary R Hunter; Guang Yang; Lian Xu; Steven P Treon
Journal:  Clin Cancer Res       Date:  2018-04-16       Impact factor: 12.531

5.  Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

Authors:  Steven P Treon; Kirsten Meid; Christina Tripsas; Leonard T Heffner; Herbert Eradat; Ashraf Z Badros; Lian Xu; Zachary R Hunter; Guang Yang; Christopher J Patterson; Joshua Gustine; Jorge J Castillo; Jeffrey Matous; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2016-11-11       Impact factor: 12.531

6.  Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

Authors:  Steven P Treon; Yang Cao; Lian Xu; Guang Yang; Xia Liu; Zachary R Hunter
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113

7.  Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.

Authors:  Leomar Y Ballester; Sanam Loghavi; Rashmi Kanagal-Shamanna; Bedia A Barkoh; Pei Lin; L Jeffrey Medeiros; Rajyalakshmi Luthra; Keyur P Patel
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-05-05

8.  The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.

Authors:  Y Cao; Z R Hunter; X Liu; L Xu; G Yang; J Chen; C J Patterson; N Tsakmaklis; S Kanan; S Rodig; J J Castillo; S P Treon
Journal:  Leukemia       Date:  2014-06-10       Impact factor: 11.528

9.  Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.

Authors:  H A F Stessman; A Mansoor; F Zhan; S Janz; M A Linden; L B Baughn; B Van Ness
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

Review 10.  Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

Authors:  Prashant Kapoor; Stephen M Ansell; Rafael Fonseca; Asher Chanan-Khan; Robert A Kyle; Shaji K Kumar; Joseph R Mikhael; Thomas E Witzig; Michelle Mauermann; Angela Dispenzieri; Sikander Ailawadhi; A Keith Stewart; Martha Q Lacy; Carrie A Thompson; Francis K Buadi; David Dingli; William G Morice; Ronald S Go; Dragan Jevremovic; Taimur Sher; Rebecca L King; Esteban Braggio; Ann Novak; Vivek Roy; Rhett P Ketterling; Patricia T Greipp; Martha Grogan; Ivana N Micallef; P Leif Bergsagel; Joseph P Colgan; Nelson Leung; Wilson I Gonsalves; Yi Lin; David J Inwards; Suzanne R Hayman; Grzegorz S Nowakowski; Patrick B Johnston; Steven J Russell; Svetomir N Markovic; Steven R Zeldenrust; Yi L Hwa; John A Lust; Luis F Porrata; Thomas M Habermann; S Vincent Rajkumar; Morie A Gertz; Craig B Reeder
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777
View more
  7 in total

Review 1.  Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.

Authors:  Saurabh Zanwar; Jithma P Abeykoon
Journal:  Ther Adv Hematol       Date:  2022-04-29

Review 2.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

3.  Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

Authors:  Jorge J Castillo; Kirsten Meid; Catherine A Flynn; Jiaji Chen; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Guang Yang; Zachary Hunter; Steven P Treon
Journal:  Blood Adv       Date:  2020-08-25

4.  Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.

Authors:  Marie José Kersten; Karima Amaador; Monique C Minnema; Josephine M I Vos; Kazem Nasserinejad; Marcel Kap; Efstathios Kastritis; Maria Gavriatopoulou; Willem Kraan; Martine E D Chamuleau; Dries Deeren; Lidwine W Tick; Jeanette K Doorduijn; Fritz Offner; Lara H Böhmer; Roberto D Liu; Steven T Pals; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2021-08-13       Impact factor: 44.544

5.  Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome.

Authors:  Mario Ojeda-Uribe; Valérie Rimelen; Cathérine Marzullo
Journal:  J Blood Med       Date:  2020-02-13

6.  Waldenström's macroglobulinemia front line treatment.

Authors:  Alessandra Tedeschi; Anna Maria Frustaci
Journal:  Hemasphere       Date:  2019-06-30

Review 7.  Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.

Authors:  Anagha Deshpande; Javier Munoz
Journal:  Ther Clin Risk Manag       Date:  2022-06-23       Impact factor: 2.755
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.